



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/SE/2018-19

Date: 14th August, 2018

To,
Department of Corporate Service,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release for June, 2018

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 14th August, 2018.

This is for your information and records.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

V. S. Ranade

Vibhav S. Ranade
Company Secretary & Compliance Officer
ICSI M. No. A35284



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press Release for June, 2018:

In June quarter Company recorded highest quarterly revenue of Rs. 375.21 crores on the account of good demand and positive price variance in API segment. In exports there was a volume growth of around 27.3% due to good demand and more customer approvals. Volume growth of around 51.5% in domestic market is mainly because of GST affected Jun'17 quarter.

Consolidated EBITDA for the quarter ended Jun'18 is Rs. 53.53 crores, up by 51% and Consolidated Profit after tax for the quarter ended Jun'18 is Rs. 23.37 crores, up by 105.5%. However, the growth numbers are higher as Jun'17 quarter was badly impacted due to GST transitioning. Operating margins slightly reduced on the account of notional foreign exchange loss by around 1.3% and also due to higher raw material prices by around 2%. Once the prices stabilize, we expect the operating margins to restore to original levels. Company was able to reduce working capital requirement thus reducing the Debt/Equity ratio to 1.11 as of Jun'18.

Company has submitted final response to USFDA on Jun'18 end for the latest re-inspection, which took place in Dec'17. Company is focusing more on therapeutic categories related to lifestyle related diseases and currently antibiotic contributes to around 34% of its total API segment revenues.

For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer